Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rang in Aktien #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Aktienkurs
$1.89
Zuletzt synchronisiert: 2022-12-16
Marktkapitalisierung
$24.38M
Veränderung (1 Tag)
8.62%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Yumanity Therapeutics, Inc. (YMTX)

Kategorie

Aktien-Split-Historie für Yumanity Therapeutics, Inc. (YMTX)
Die Aktie Yumanity Therapeutics, Inc. (Symbol: YMTX) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 19, 2026 statt.
Eine YMTX-Aktie, die vor dem Aug 19, 2026 gekauft wurde, entspricht heute 0 YMTX-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH